STXS - Stereotaxis Inc Stock Price, Fair Value and News

2.69USD-0.02 (-0.74%)Market Closed

Market Summary

USD2.69-0.02

Market Closed

-0.74%

STXS Stock Price

View Fullscreen

STXS RSI Chart

STXS Valuation

Market Cap

220.9M

Price/Earnings (Trailing)

-10.67

Price/Sales (Trailing)

8.25

Price/Free Cashflow

-24.17

STXS Price/Sales (Trailing)

STXS Profitability

Operating Margin

55.51%

Return on Equity

-126.74%

Return on Assets

-49.42%

Free Cashflow Yield

-4.14%

STXS Fundamentals

STXS Revenue

Revenue (TTM)

26.8M

Rev. Growth (Yr)

-37.47%

Rev. Growth (Qtr)

-41.47%

STXS Earnings

Earnings (TTM)

-20.7M

Earnings Growth (Yr)

-21.31%

Earnings Growth (Qtr)

6.13%

Breaking Down STXS Revenue

Last 7 days

-11.5%

Last 30 days

8.5%

Last 90 days

47.8%

Trailing 12 Months

53.7%

How does STXS drawdown profile look like?

STXS Financial Health

Current Ratio

2.51

Debt/Equity

0.01

Debt/Cashflow

-37.51

STXS Investor Care

Shares Dilution (1Y)

9.44%

Diluted EPS (TTM)

-0.27

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	27.7M	29.4M	29.5M	26.8M
2022	33.4M	30.5M	29.1M	28.1M
2021	29.5M	33.2M	33.6M	35.0M
2020	27.6M	26.2M	26.7M	26.6M
2019	29.0M	28.6M	29.3M	28.9M
2018	30.5M	0	29.9M	29.3M
2017	30.5M	31.1M	30.9M	31.1M
2016	36.8M	35.0M	34.1M	32.2M
2015	36.2M	37.8M	38.2M	37.7M
2014	38.0M	36.3M	34.3M	35.0M
2013	42.7M	41.9M	41.2M	38.0M
2012	44.0M	43.0M	46.0M	46.6M
2011	53.7M	50.2M	44.9M	42.0M
2010	0	52.1M	53.1M	54.1M
2009	0	0	0	51.1M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Stereotaxis Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 02, 2024	menawat arun swarup	acquired	-	-	64,935	-
Jan 02, 2024	curet myriam	acquired	-	-	64,935	-
Jan 02, 2024	levin ross b	acquired	-	-	64,935	-
Jan 02, 2024	fischel nathan	acquired	-	-	64,935	-
Jan 02, 2024	benfer david	acquired	-	-	64,935	-
Jan 02, 2024	messey robert j	acquired	-	-	64,935	-
Dec 15, 2023	isaac paul j	bought	19,023	1.72	11,060	-
Nov 30, 2023	isaac paul j	bought	4,380	1.56	2,808	-
Nov 22, 2023	isaac paul j	bought	27.00	1.5	18.00	-
Nov 21, 2023	isaac paul j	bought	9,180	1.53	6,000	-

Which funds bought or sold STXS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 11, 2024	GSG Advisors LLC	new	-	78,175	78,175	0.03%
Apr 11, 2024	Roble, Belko & Company, Inc	unchanged	-	8,000	26,000	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	unchanged	-	3,060	31,500	-%
Mar 11, 2024	VANGUARD GROUP INC	added	11.14	796,922	4,246,430	-%
Feb 26, 2024	Virtu Financial LLC	new	-	37,000	37,000	-%
Feb 16, 2024	PRICE T ROWE ASSOCIATES INC /MD/	unchanged	-	10,000	103,000	-%
Feb 15, 2024	BARCLAYS PLC	reduced	-83.82	-29,000	6,000	-%
Feb 15, 2024	State of Wyoming	added	27.91	125,289	425,908	0.08%
Feb 15, 2024	JANE STREET GROUP, LLC	new	-	278,946	278,946	-%
Feb 14, 2024	AlphaCentric Advisors LLC	unchanged	-	102,000	1,050,000	0.70%

Are Funds Buying or Selling STXS?

Are funds buying STXS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own STXS

No. of Funds

Unveiling Stereotaxis Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	redmile group, llc	4.2%	3,402,443	SC 13G/A
Feb 14, 2023	redmile group, llc	8.8%	7,097,616	SC 13G/A
Feb 14, 2022	redmile group, llc	9.1%	7,308,325	SC 13G/A
Feb 03, 2022	arbiter partners capital management llc	3.0%	2,208,952	SC 13G/A
Jun 16, 2021	kiani joe e	9.99%	7,540,515	SC 13G
Feb 17, 2021	arbiter partners capital management llc	5.7%	4,208,952	SC 13G/A
Feb 16, 2021	redmile group, llc	9.9%	7,833,765	SC 13G/A
Feb 12, 2021	opaleye management inc.	4.10%	9	SC 13G/A
Feb 14, 2020	opaleye management inc.	6.16%	9	SC 13G/A
Feb 14, 2020	redmile group, llc	9.9%	7,053,462	SC 13G/A

Recent SEC filings of Stereotaxis Inc

View All Filings

Date Filed	Form Type	Document
Apr 08, 2024	DEFA14A	DEFA14A
Apr 04, 2024	DEFA14A	DEFA14A
Apr 04, 2024	DEF 14A	DEF 14A
Apr 04, 2024	4	Insider Trading
Mar 08, 2024	10-K	Annual Report
Mar 04, 2024	8-K	Current Report
Feb 14, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Stereotaxis Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	188.9B	40.1B	-5.73%	4.72%	33.01	4.71	-8.12%	-17.45%
BDX	67.8B	19.5B	-0.88%	-8.17%	53.97	3.48	4.02%	-22.04%
ALGN	22.9B	3.9B	-3.10%	-11.00%	51.41	5.92	3.42%	23.09%
BAX	20.3B	14.8B	-3.77%	-6.99%	7.66	1.37	2.12%	209.17%
MID-CAP
ATR	9.1B	3.5B	-1.99%	15.94%	32.07	2.62	4.97%	18.89%
HSIC	9.1B	12.3B	-5.16%	-14.19%	21.85	0.74	-2.44%	-22.68%
BIO	8.8B	2.7B	-9.88%	-37.29%	-13.77	3.29	-4.68%	82.43%
XRAY	6.4B	4.0B	-5.94%	-24.93%	-47.62	1.62	1.10%	85.84%
AXNX	3.4B	366.4M	-0.71%	17.46%	-565.84	9.37	33.86%	89.83%
PDCO	2.3B	6.6B	-6.94%	-4.63%	11.73	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-3.79%	-17.24%	-1.94	0.41	7.73%	-1066.14%
ANIK	376.4M	166.7M	-0.35%	-8.55%	-4.55	2.26	6.67%	-456.34%
ANGO	253.5M	324.0M	17.88%	-30.36%	-1.32	0.78	-3.19%	-337.41%
APYX	47.8M	52.3M	-22.91%	-54.00%	-2.55	0.91	17.61%	19.28%
AEMD	3.8M	3.7M	-16.18%	262.50%	-0.31	1.01	5.77%	8.23%

Stereotaxis Inc News

Latest updates

Stereotaxis Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-41.5%	4,565	7,799	7,859	6,548	7,301	7,657	6,152	7,037	8,241	9,106	9,051	8,623	6,825	8,704	5,345	5,756	6,893	8,202	6,798	7,010	7,268
Cost Of Revenue	-51.1%	1,827	3,740	3,672	2,672	2,992	3,090	1,482	2,113	2,291	4,372	2,519	2,607	1,603	4,025	1,085	951	1,745	1,832	1,147	1,412	1,429
Gross Profit	-32.5%	2,738	4,059	4,187	3,876	4,309	4,567	4,670	4,924	5,950	4,734	6,532	6,016	5,222	4,678	4,260	4,805	5,147	6,370	5,651	5,598	5,839
Operating Expenses	-17.1%	8,042	9,698	9,464	9,495	8,765	9,619	9,849	9,013	9,299	9,354	9,923	7,544	6,399	6,241	6,182	6,857	6,334	6,411	7,110	7,737	6,425
S&GA Expenses	-9.9%	2,791	3,097	3,340	3,148	2,989	3,111	3,279	2,946	3,046	2,910	3,045	2,947	2,898	2,823	2,542	2,915	3,066	3,121	3,237	3,310	3,054
R&D Expenses	-17.1%	2,212	2,668	2,647	2,746	2,400	2,818	2,893	2,447	2,615	2,500	2,717	2,367	2,098	1,953	1,977	2,109	1,616	1,751	2,695	2,959	2,224
Interest Expenses	-100.0%	-	270	293	272	318	135	45.00	3.00	-5.50	1.00	-3.00	-4.00	-4.24	-9.93	567*	81.00	102	85.00	32.00	17.00	-14.05
Net Income	6.1%	-5,040	-5,369	-4,957	-5,347	-4,154	-4,917	-5,134	-4,086	-3,354	-4,619	-1,211	-1,532	-1,180	-1,572	-1,921	-1,971	-1,084	44.00	-1,427	-2,122	-569
Net Income Margin	-15.1%	-0.77*	-0.67*	-0.66*	-0.71*	-0.65*	-0.60*	-0.56*	-0.40*	-0.31*	-0.25*	-0.17*	-0.21*	-	-	-	-	-	-	-	-	-
Free Cashflow	-152.2%	-2,439	-967	-2,931	-2,802	-2,552	-2,533	-1,137	-2,193	-1,219	-1,456	34.00	-305	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-5.9%	42.00	45.00	48.00	51.00	53.00	56.00	57.00	57.00	61.00	62.00	57.00	59.00	55.00	57.00	57.00	42.00	44.00	43.00	21.00	22.00	19.00
Current Assets	-6.3%	33.00	36.00	39.00	41.00	43.00	46.00	47.00	47.00	51.00	53.00	55.00	57.00	53.00	54.00	53.00	37.00	39.00	38.00	16.00	16.00	18.00
Cash Equivalents	-7.0%	21.00	22.00	23.00	6.00	9.00	31.00	33.00	35.00	40.00	40.00	42.00	42.00	44.00	44.00	44.00	28.00	30.00	32.00	8.00	9.00	11.00
Inventory	24.1%	8.00	7.00	8.00	9.00	8.00	8.00	8.00	5.00	4.00	4.00	4.00	4.00	3.00	3.00	5.00	3.00	2.00	2.00	2.00	1.00	1.00
Net PPE	-4.0%	3.00	3.00	4.00	4.00	4.00	3.00	3.00	3.00	3.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	-1.2%	20.00	20.00	21.00	21.00	21.00	23.00	21.00	20.00	22.00	22.00	15.00	18.00	15.00	17.00	16.00	14.00	15.00	15.00	17.00	17.00	11.00
Current Liabilities	1.6%	13.00	13.00	14.00	14.00	14.00	16.00	14.00	11.00	13.00	14.00	13.00	17.00	14.00	13.00	14.00	12.00	12.00	11.00	13.00	12.00	10.00
Short Term Borrowings	-	-	-	-	-	-	-	-	-	-	-	-	2.00	1.00	0.00	2.00	-	-	-	-	-	-
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	0.00	1.00	2.00	-	-	-	-	-	-	-
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	-	0.00	1.00	2.00	-	-	-	-	-	-	-
Shareholder's Equity	-12.7%	16.00	19.00	21.00	24.00	26.00	28.00	30.00	32.00	34.00	35.00	36.00	35.00	35.00	35.00	36.00	22.00	23.00	23.00	-	-	1.00
Retained Earnings	-0.9%	-537	-532	-527	-522	-516	-512	-507	-502	-498	-495	-490	-489	-487	-486	-485	-483	-481	-480	-480	-478	-476
Additional Paid-In Capital	0.5%	554	551	549	546	543	541	538	535	533	530	527	524	523	522	521	505	504	503	479	478	478
Shares Outstanding	-100.0%	-	82.00	81.00	77.00	76.00	76.00	76.00	76.00	76.00	76.00	75.00	75.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	-	-	111	-	-	-	578	-	-	-	234	-	-	-	112	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-152.2%	-2,439	-967	-2,931	-2,802	-2,552	-2,533	-1,137	-2,193	-1,219	-1,456	34.00	-305	308	-482	-1,170	-2,165	-1,914	-405	-518	-1,776	-777
Share Based Compensation	-1.4%	2,636	2,673	2,659	2,655	2,670	2,695	2,697	2,514	2,610	2,597	2,785	1,371	756	756	935	722	431	426	325	148	95.00
Cashflow From Investing	100.0%	-	-10.00	20,124	-349	-20,085	-205	-650	-1,154	-1,196	-51.00	-116	-34.00	-	-	-	-	-13.65	-6.00	-	-9.83	-9.93
Cashflow From Financing	4.0%	26.00	25.00	-26.00	56.00	61.00	48.00	57.00	54.00	11.00	134	120	282	36.00	73.00	17,223	8.00	460	23,590	-49.96	32.00	13.00

STXS Income Statement

2023-12-31

Statements of Operations - USD ($) $ in Thousands	12 Months Ended
Statements of Operations - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Revenue:
Total revenue	$ 26,771	$ 28,147
Cost of revenue:
Total cost of revenue	11,911	9,677
Gross margin	14,860	18,470
Operating expenses:
Research and development	10,273	10,558
Sales and marketing	12,376	12,325
General and administrative	14,050	14,363
Total operating expenses	36,699	37,246
Operating loss	(21,839)	(18,776)
Other income	30
Interest income, net	1,096	484
Net loss	(20,713)	(18,292)
Cumulative dividend on convertible preferred stock	(1,343)	(1,343)
Net loss attributable to common stockholders	$ (22,056)	$ (19,635)
Net loss per share attributable to common stockholders:
Basic	$ (0.27)	$ (0.26)
Diluted	$ (0.27)	$ (0.26)
Weighted average number of common shares and equivalents:
Basic	80,702,358	76,061,183
Diluted	80,702,358	76,061,183
Systems [Member]
Revenue:
Total revenue	$ 8,739	$ 6,845
Cost of revenue:
Total cost of revenue	8,058	5,802
Disposables Service and Accessories [Member]
Revenue:
Total revenue	18,032	21,302
Cost of revenue:
Total cost of revenue	$ 3,853	$ 3,875

STXS Balance Sheet

2023-12-31

Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 19,818	$ 8,586
Restricted cash - current	525	525
Short-term investments		19,844
Accounts receivable, net of allowance of $672 and $235 at 2023 and 2022, respectively	3,822	5,090
Inventories, net	8,426	7,876
Prepaid expenses and other current assets	676	1,325
Total current assets	33,267	43,246
Property and equipment, net	3,304	3,831
Restricted cash	219	744
Operating lease right-of-use assets	4,982	5,384
Prepaid and other non-current assets	137	208
Total assets	41,909	53,413
Current liabilities:
Accounts payable	3,190	3,270
Accrued liabilities	2,972	3,306
Deferred revenue	6,657	7,342
Current portion of operating lease liabilities	428	373
Total current liabilities	13,247	14,291
Long-term deferred revenue	1,637	1,654
Operating lease liabilities	5,062	5,488
Other liabilities	43	51
Total liabilities	19,989	21,484
Series A - Convertible preferred stock:
Convertible preferred stock, Series A, par value $0.001; 22,358 and 22,383 shares outstanding at 2023 and 2022, respectively	5,577	5,583
Stockholders’ equity:
Convertible preferred stock, Series B, par value $0.001; 10,000,000 shares authorized, 5,610,121 shares outstanding at 2022		6
Common stock, par value $0.001; 300,000,000 shares authorized, 80,949,697 and 74,874,459 shares issued at 2023 and 2022, respectively	81	75
Additional paid in capital	554,148	543,438
Treasury stock, 4,015 shares at 2023 and 2022	(206)	(206)
Accumulated deficit	(537,680)	(516,967)
Total stockholders’ equity	16,343	26,346
Total liabilities and stockholders’ equity	$ 41,909	$ 53,413

About Stereotaxis Inc

Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company also provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane, full-power x-ray system, including c-arm, powered table, motorized boom, and large high-definition monitors for a robotic interventional operating room. In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; and CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters. Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. The company markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with Osypka AG to develop a magnetic ablation catheter using Stereotaxis' robotic technology. Stereotaxis, Inc. was incorporated in 1990 and is headquartered in Saint Louis, Missouri.

CEO	Dr. David Leo Fischel C.A.I.A., C.F.A., C.P.A., M.B.A., CFA, CPA
WEBSITE	stereotaxis.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	130

Stereotaxis Inc Frequently Asked Questions

What is the ticker symbol for Stereotaxis Inc? What does STXS stand for in stocks?

STXS is the stock ticker symbol of Stereotaxis Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Stereotaxis Inc (STXS)?

As of Mon Apr 15 2024, market cap of Stereotaxis Inc is 220.93 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of STXS stock?

You can check STXS's fair value in chart for subscribers.

What is the fair value of STXS stock?

You can check STXS's fair value in chart for subscribers. The fair value of Stereotaxis Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Stereotaxis Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for STXS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Stereotaxis Inc a good stock to buy?

The fair value guage provides a quick view whether STXS is over valued or under valued. Whether Stereotaxis Inc is cheap or expensive depends on the assumptions which impact Stereotaxis Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for STXS.

What is Stereotaxis Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Apr 15 2024, STXS's PE ratio (Price to Earnings) is -10.67 and Price to Sales (PS) ratio is 8.25. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. STXS PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Stereotaxis Inc's stock?

In the past 10 years, Stereotaxis Inc has provided -0.029 (multiply by 100 for percentage) rate of return.